• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The repeatability of tests for dry eye signs and symptoms in the dry eye assessment and management (DREAM) study.干眼评估与管理(DREAM)研究中干眼体征和症状测试的可重复性。
Cont Lens Anterior Eye. 2025 Apr;48(2):102322. doi: 10.1016/j.clae.2024.102322. Epub 2024 Oct 30.
2
Real-world practice patterns for dry eye diagnosis: a multicenter observational study in Taiwan.干眼症诊断的真实世界实践模式:台湾的一项多中心观察性研究。
Jpn J Ophthalmol. 2025 May;69(3):343-350. doi: 10.1007/s10384-025-01175-6. Epub 2025 Mar 8.
3
Relative importance of tear homeostatic signs for the diagnosis of dry eye disease.泪液稳态指标对干眼疾病诊断的相对重要性
Ocul Surf. 2025 Apr;36:151-155. doi: 10.1016/j.jtos.2025.01.010. Epub 2025 Jan 21.
4
Intereye Agreement in Dry-Eye Signs in the DREAM Study: Implications for Future Dry-Eye Trials.DREAM研究中干眼体征的双眼一致性:对未来干眼试验的启示
Cornea. 2025 Feb 1;44(2):149-156. doi: 10.1097/ICO.0000000000003605. Epub 2024 Jul 30.
5
Punctal occlusion for dry eye syndrome.用于干眼症的泪点闭塞术。
Cochrane Database Syst Rev. 2017 Jun 26;6(6):CD006775. doi: 10.1002/14651858.CD006775.pub3.
6
Autologous serum eye drops for dry eye.用于干眼症的自体血清眼药水。
Cochrane Database Syst Rev. 2017 Feb 28;2(2):CD009327. doi: 10.1002/14651858.CD009327.pub3.
7
Topical corticosteroids for dry eye.局部皮质类固醇治疗干眼。
Cochrane Database Syst Rev. 2022 Oct 21;10(10):CD015070. doi: 10.1002/14651858.CD015070.pub2.
8
Efficacy of meibomian gland expression combined with Home-Based therapy in the management of dry eye Disease: A systematic review and Meta-Analysis.睑板腺按摩联合家庭治疗干眼病的疗效:系统评价和 Meta 分析。
Cont Lens Anterior Eye. 2024 Apr;47(2):102107. doi: 10.1016/j.clae.2023.102107. Epub 2023 Dec 22.
9
Association of Dry Eye Symptoms and Signs in Patients with Dry Eye Disease.干眼疾病患者干眼症状和体征的相关性。
Ophthalmic Epidemiol. 2024 Jun;31(3):274-282. doi: 10.1080/09286586.2023.2248629. Epub 2023 Aug 17.
10
Association of Conjunctival Cell HLA-DR Expression with the Severity of Signs and Symptoms of Dry Eye Disease at Baseline in the NORTHERN LIGHTS Phase 2 Trial.在“北极光”2期试验中,结膜细胞HLA - DR表达与干眼疾病基线时体征和症状严重程度的关联。
Curr Eye Res. 2025 Jun;50(6):567-571. doi: 10.1080/02713683.2025.2469254. Epub 2025 Mar 7.

本文引用的文献

1
Intereye Agreement in Dry-Eye Signs in the DREAM Study: Implications for Future Dry-Eye Trials.DREAM研究中干眼体征的双眼一致性:对未来干眼试验的启示
Cornea. 2025 Feb 1;44(2):149-156. doi: 10.1097/ICO.0000000000003605. Epub 2024 Jul 30.
2
An Automated Grading System Based on Topological Features for the Evaluation of Corneal Fluorescein Staining in Dry Eye Disease.一种基于拓扑特征的自动评分系统用于干眼疾病中角膜荧光素染色的评估
Diagnostics (Basel). 2023 Nov 26;13(23):3533. doi: 10.3390/diagnostics13233533.
3
Changes caused by fluorescein in tear film by hybrid break-up time test- part one; on quantitative values.通过混合泪膜破裂时间试验观察荧光素对泪膜的影响——第一部分:关于定量值
Photodiagnosis Photodyn Ther. 2022 Dec;40:103137. doi: 10.1016/j.pdpdt.2022.103137. Epub 2022 Sep 29.
4
Automated vs. human evaluation of corneal staining.自动评估与人工评估角膜染色。
Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2605-2612. doi: 10.1007/s00417-022-05574-0. Epub 2022 Mar 31.
5
Quantitative analysis of morphological and functional features in Meibography for Meibomian Gland Dysfunction: Diagnosis and Grading.睑板腺功能障碍的睑板造影术形态学和功能特征的定量分析:诊断与分级
EClinicalMedicine. 2021 Sep 11;40:101132. doi: 10.1016/j.eclinm.2021.101132. eCollection 2021 Oct.
6
Deep learning-based automatic meibomian gland segmentation and morphology assessment in infrared meibography.基于深度学习的红外睑板腺图像中睑板腺自动分割与形态评估。
Sci Rep. 2021 Apr 7;11(1):7649. doi: 10.1038/s41598-021-87314-8.
7
An automated and multiparametric algorithm for objective analysis of meibography images.一种用于睑板腺图像客观分析的自动化多参数算法。
Quant Imaging Med Surg. 2021 Apr;11(4):1586-1599. doi: 10.21037/qims-20-611.
8
Repeatability of Non-invasive Keratograph Break-Up Time measurements obtained using Oculus Keratograph 5M.使用 Oculus Keratograph 5M 进行非侵入性角膜破裂时间测量的可重复性。
Int Ophthalmol. 2021 Jul;41(7):2473-2483. doi: 10.1007/s10792-021-01802-4. Epub 2021 Mar 16.
9
Inter-week variation of meibometry and tear break-up time in healthy subjects.健康受试者的睑板腺测量和泪膜破裂时间的周间变化。
Clin Exp Optom. 2021 Aug;104(6):691-697. doi: 10.1080/08164622.2021.1878815. Epub 2021 Mar 3.
10
The development and evaluation of the new Ocular Surface Disease Index-6.新眼表疾病指数-6 的研制与评估。
Ocul Surf. 2019 Oct;17(4):817-821. doi: 10.1016/j.jtos.2019.08.008. Epub 2019 Aug 20.

干眼评估与管理(DREAM)研究中干眼体征和症状测试的可重复性。

The repeatability of tests for dry eye signs and symptoms in the dry eye assessment and management (DREAM) study.

作者信息

Chen Anna, Augello Patrick, Asbell Penny, Ying Gui-Shuang

机构信息

University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.

Temple University School of Public Health, Philadelphia, PA, United States.

出版信息

Cont Lens Anterior Eye. 2025 Apr;48(2):102322. doi: 10.1016/j.clae.2024.102322. Epub 2024 Oct 30.

DOI:10.1016/j.clae.2024.102322
PMID:39477774
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11911092/
Abstract

PURPOSE

To assess the repeatability of measures for dry eye disease (DED) symptoms and signs in the DREAM study.

METHODS

At screening and baseline visits approximately 2 weeks apart, participants were assessed for symptoms by Ocular Surface Disease Index (OSDI) and Brief Ocular Discomfort Index (BODI), and signs by the same physician in the same order: tear break-up time (TBUT), corneal staining, conjunctival staining, Meibomian gland evaluation, and the Schirmer test. The repeatability of DED symptoms and signs was assessed by interclass correlation coefficient (ICC), 95 % limits of agreement, and the percent of eyes with inter-visit difference above the clinically significant threshold.

RESULTS

Among 1046 eyes (523 participants), ICC for signs ranged from 0.53 (TBUT) to 0.73 (corneal staining). A substantial percentage of eyes showed clinically significant inter-visit differences: ≥2 points in 17.8 % of eyes for conjunctival staining; ≥3 points in 18.8 % for corneal staining; >2 s in 14.1 % for TBUT; ≥5 mm/5 min in 29.9 % for the Schirmer test, and ≥ 2 points in 27.5 % for Meibomian gland plugging and lid secretion. The OSDI and BODI had ICC of 0.64 and 0.63 respectively, and nearly 40 % of participants had inter-visit score differences ≥ 10 points.

CONCLUSION

In DREAM participants with moderate-to-severe DED, DED signs and symptoms had moderate repeatability, with ocular surface staining scores being the most repeatable and TBUT the least repeatable. A notable percentage of participants had inter-visit differences above the clinically meaningful threshold. These test-retest variabilities in DED signs and symptoms should be considered for designing clinical trials and monitoring disease progression.

摘要

目的

在DREAM研究中评估干眼疾病(DED)症状和体征测量的可重复性。

方法

在间隔约2周的筛查和基线访视时,由同一位医生按相同顺序对参与者进行症状评估,采用眼表疾病指数(OSDI)和简易眼不适指数(BODI),体征评估包括泪膜破裂时间(TBUT)、角膜染色、结膜染色、睑板腺评估和泪液分泌试验。通过组内相关系数(ICC)、95%一致性界限以及访视间差异超过临床显著阈值的眼的百分比来评估DED症状和体征的可重复性。

结果

在1046只眼(523名参与者)中,体征的ICC范围为0.53(TBUT)至0.73(角膜染色)。相当比例的眼显示出具有临床意义的访视间差异:结膜染色≥2分的眼占17.8%;角膜染色≥3分的眼占18.8%;TBUT>2秒的眼占14.1%;泪液分泌试验≥5毫米/5分钟的眼占29.9%;睑板腺堵塞和睑部分泌≥2分的眼占27.5%。OSDI和BODI的ICC分别为0.64和0.63,近40%的参与者访视间得分差异≥10分。

结论

在患有中重度DED的DREAM参与者中,DED体征和症状具有中等可重复性,眼表染色评分的可重复性最高,TBUT的可重复性最低。相当比例的参与者访视间差异超过临床有意义的阈值。在设计临床试验和监测疾病进展时应考虑DED体征和症状的这些重测变异性。